Peer-reviewed veterinary case report
Chemotherapy and surgery outcomes for injection-site sarcoma in 21
By Bray, J & Polton, G·Published in Veterinary and comparative oncology·2016·Veterinary Teaching Hospital·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection-site sarcoma: results in 21 cats.
- Species:
- cat
Plain-English summary
A group of 21 cats with injection-site sarcoma, a type of cancer that can develop at vaccination sites, underwent a combination of chemotherapy and surgery. They first received three cycles of chemotherapy with a drug called epirubicin, followed by surgery to remove the tumor and surrounding tissue. After surgery, they continued with three more cycles of chemotherapy. Most of the cats remained healthy for a long time, with only a few experiencing a return of the tumor. This treatment approach showed better results compared to older methods, with many cats living longer without signs of cancer.
People also search for: cat injection-site sarcoma treatment · feline cancer chemotherapy · cat tumor surgery recovery
Abstract
This study assesses the outcome of two combined treatment strategies for the treatment of feline injection-site sarcoma (FISS). Twenty-one cats with primary or recurrent FISS received 3 cycles of neoadjuvant chemotherapy with epirubicin (25 mg m(-2) ), then an anatomical resection of the entire muscle compartment containing the tumour was performed based on the findings of co-axial imaging. Cats then received a further 3 cycles of adjuvant chemotherapy. Follow-up was performed by telephone contact with a median follow-up time of 1072 days. Three cats (14%) developed local tumour recurrence at days 264, 664 and 1573 after surgery. A median survival time could not be calculated as over 80% of the study population remained alive or were censored due to death from other causes. When compared to historical controls, the results of this study demonstrate superior rates of tumour-free survival and disease-free interval.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24502401/